Sanochemia pharmaceuticals
| Sanochemia pharmaceuticals
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | AT0000776307 |
| founding | November 13, 1990 |
| Seat |
Vienna , Austria
|
| management |
|
| Number of employees | 189 (September 30, 2007) |
| sales | 29.6 million euros (September 30, 2007) |
| Branch | Pharmaceutical company, contract manufacturer |
| Website | www.sanochemia.at |
The Sanochemia Pharmazeutika AG is a medium-sized Austrian pharmaceutical company and is based in Vienna . The main business activities are the contract manufacturing of active ingredients for other pharmaceutical companies as well as the manufacture and sale of diagnostics . The company has been listed on the Frankfurt Stock Exchange since 1999 , originally in the Neuer Markt segment , today on the Basic Board .
In December 2019, the company filed for bankruptcy . In April 2020 it was announced that the Province of Burgenland would purchase the assets through Wirtschaft Burgenland GmbH (WiBuG) with a private consortium and transfer them to a newly founded GmbH. 49.90 percent of the newly created company would be held by EOSS Technology GmbH , 35.81 percent by beimagine GmbH and 14.29 percent by WiBuG. The state of Burgenland assumes liability in the amount of three million euros.
history
The company Sanochemia has its origins in the pharmacy “ zur golden crown” (Anton von Waldheim KG), which was founded in 1441 and still exists today . The industrial production of pharmaceuticals began in 1869 with so-called house specialties , u. a. the degreasing tablets Waldheim or the Tonicum Waldheim . From 1937 the production of pharmaceuticals from the pharmacy was outsourced. In 1939 the then company Waldheim Pharmazeutika GmbH began research on ergot alkaloids , which in 1948 led to the introduction of the now obsolete drug Neovegeton .
Since the 1950s, the company has been dealing with the active ingredient galantamine , which was initially isolated from snowdrops (botanical name Galanthus ). The chemical synthesis of the active ingredient was later also achieved in collaboration with the Vienna University of Technology . The patent for the synthesis process of galantamine, granted in 1996, represents one of the most important economic foundations of the company today.
In 1972 Werner Frantsits acquired the Waldheim company. In the 1970s the company grew through acquisitions of companies, including a. also the company Sanochemia, which was transformed into Sanochemia Pharmazeutika AG in 1990. The Sanochemia Holding , founded in Switzerland in 1976 and later relocated to Malta , took over the function of a parent company from 1992 onwards . From 1997 the veterinary pharmaceutical activities were combined in Alvetra-Werfft AG. The nucleus of the group of companies, the Waldheim company, was merged with Sanochemia Pharmazeutika AG in September 1998.
The IPO took place in 1999 in the Neuer Markt . In 2000, Sanochemia took over the German company Goldham Pharma, initially 50% and later 75%. From 2001 Sanochemia expanded increasingly internationally. In 2006 there was a majority stake in the small Innsbruck company AlcaSynn. After the Neuer Markt was discontinued, the share moved to the Prime Standard , then to the Entry Standard in 2013 and to the Basic Board after its inclusion in 2017 .
present
Business activity
The two main business areas are the contract manufacturing of active ingredients for other pharmaceutical companies as well as the manufacturing and distribution of diagnostics.
For example, Sanochemia produces the active ingredient galantamine for the anti- dementia Reminyl for Johnson & Johnson and Shire and the active ingredient torasemide for Hoffmann-La Roche . The company's synthesis and production site is in Neufeld an der Leitha .
Products in the self-distribution of Sanochemia are z. B. generic X-ray contrast media (including barium sulfate as Barilux , amidotrizoic acid as Gastrolux or Urolux Retro , Iopamidol as Unilux , gadopentetate dimeglumine as MR-Lux , and gadoteric acid as Cyclolux ). In 2012, the national and international distribution of radiological diagnostics was awarded in cooperation with the German company CS-Diagnostics GmbH . Since 1992, Sanochemia has also been selling the self-developed HIV test Fluorognost IFA HIV-1 , which is approved in the USA as an alternative to the Western blot confirmation test.
Research and Development
Sanochemia is currently investigating galantamine and galantamine derivatives for their suitability in other areas of application. A second development project to the approval ability of the muscle relaxant ' tolperisone reached in the United States. In addition, PVP - hypericin is being developed as a photoactive agent for the diagnosis of bladder tumors and a peripherally active opioid for the treatment of acute and chronic pain.
Web links
Individual evidence
- ↑ sanochemia.at: Management , accessed on January 18, 2017.
- ^ Publicly listed pharmaceutical company Sanochemia is bankrupt. In: www.msn.com. Retrieved December 10, 2019 .
- ^ Province of Burgenland takes over the insolvent Sanochemia. In: DerStandard.at . April 15, 2020, accessed April 15, 2020 .
- ^ Nowotny O .: The pharmaceutical industry in Austria. Part IV: A spirit of optimism. ( Memento from March 7, 2008 in the Internet Archive ) Österreichische Apothekerzeitung 14/2002. Accessed September 26, 2008.
- ↑ Werner Sommer: Pharmaceutical company and TU chemist synthesized active ingredient for Alzheimer's drug. TU Wien , November 27, 2000, accessed on September 26, 2008 .
- ^ Sanochemia company history
- ↑ Sanochemia acquires AlcaSynn Pharmaceuticals. In: www.finanznachrichten.de. June 9, 2006, accessed December 10, 2019 .
- ↑ Sanochemia changes to the Entry Standard